#035 ALT-erred Expectations What Went Wrong at $ALT

Biotech dreams turned into investor nightmares when $ALT stock plummeted 53% overnight after failing a key endpoint in its MASH drug trial. In this episode of Sue Wall Street, we break down the class action lawsuit accusing Altimmune of hyping results and misleading shareholders. Perfect for investors, biotech watchers, and legal buffs, this episode mixes deep-dive analysis with sharp commentary. Expect insider breakdowns, trial missteps, and the legal firestorm that followed. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.